Medable

Executive Summary

Medable is a digital health company that provides a unified, AI-powered platform to accelerate and streamline clinical trials. Its core offerings include an agentic AI trial platform, best-in-class electronic Clinical Outcome Assessment (eCOA) solutions, and tools for decentralized clinical trials (DCTs). By enabling remote data collection, AI-driven insights, and streamlined workflows, Medable helps pharmaceutical sponsors reduce trial timelines and costs while improving patient experience and data quality. The company has established a strong foothold in the rapidly growing decentralized clinical trial market, which is projected to expand as regulatory agencies increasingly endorse hybrid and remote trial models. With over a decade of experience and a focus on innovation, Medable is well-positioned to capture significant market share. However, the competitive landscape includes other DCT platform providers like Science 37 and ObvioHealth, as well as technology giants investing in healthcare AI. Medable's ability to maintain technological leadership and secure strategic partnerships will be key to its continued growth.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation AI trial design and optimization module70% success
• Q4 2026Major partnership agreement with top-10 pharma for decentralized trial platform adoption60% success
• Q2 2026Series D funding round to accelerate global expansion and AI capabilities80% success